Objective: To investigate the clinical value of ADNEX model in early diagnosis and staging of benign and malignant ovarian tumors. Method: 136 cases of ovarian cancer patients treated in our hospital were retrospectively analyzed using the ADNEX risk model and MRI data. The accuracy of the two diagnostic methods was compared with the results of pathological examination as gold standard. Results: For qualitative assessment, the accuracy and sensitivity of the ADNEX model were 78.70% and 93%, while the accuracy and sensitivity of MRI examination were 80.1%, and 90.7%, respectively. The diagnostic values of the two methods were not statistically different (P > 0.05). For ovarian tumor staging, the ADNEX model was significantly less accurate and specific for staging borderline tumor than MRI examination, although it had significantly higher sensitivity (P < 0.05). For tumors at other stages, there were no diagnostic differences between the methods (P > 0.05). Conclusion: ADNEX risk model has certain diagnostic and predictive value to distinguish benign from malignant ovarian tumors. It is useful to detect and exclude ovarian tumor. However, for early diagnosis, it is not accurate enough and further study is needed to validate this usefulness.
Introduction
The incidence of ovarian cancer ranks the third in gynecological malignancies with the highest mortality [1] . Early diagnosis and cytoreductive surgery im- prove 5-year survival rate [2] [3] . However, early screening and diagnosis of ovarian cancer is a hot but difficult spot in ovarian cancer research. The auxiliary diagnosis of ovarian cancer mainly includes the use of imaging examination and serum markers. Since ultrasound examination is simple and cost effective, it is most widely used in gynecological examination. To maximize the efficiency of early diagnosis of ovarian cancer, a number of ultrasound models have been proposed [4] [5] [6] . In 2014, the Assessment of Different NEoplasias in the adneXa (ADNEX) model was proposed to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumors [7] . It can automatically provide differentiation between benign and malignant and tumor staging information on mobile devices or websites using clinical information and ultrasound data. At present, the clinical performance of the model has not been reported in China. The aim of this study is to investigate the clinical value of the model in the early diagnosis and staging of benign and malignant ovarian tumors. 
Subjects and Methods

Subjects
Methods
Ultrasound examinations were conducted using Philips ClearVue 580 system Once relevant data were input, the property and staging of the tumor were automatically generated by the on-line ADNEX model software. 
Statistical Analysis
Data were processed using SPSS 17.0 statistical software. Enumeration data were tested using X 2 test. The data were considered statistically different when P is <0.05 and were tested using a receiver operating characteristic curve (ROC).
Results
Distinguishment of Benign and Malignant Ovarian Tumors
Among the 136 cases, 93 and 43 (including were classified as benign and malignant), (including borderline malignant) based on FIGO (2013), respectively. Based on the ADNEX model software, 70 cases were benign, and 66 cases were malignant. The accuracy, sensitivity and specificity of the ADNEX model were 78.7%, 93%, and 72%, respectively, as compared to the FIGO system. The positive and negative predictive values were 60.6% and 95.7%, respectively (Table 1) .
Staging of Ovarian Cancer by the ADNEX Model
Compared to the pathological results, the ADNEX model classified the tumors into five stages benign, borderline, I stage, II to IV stage and metastatic tumor (Table 2) . Figure 2 ). Statistical analysis showed that there were no significant difference between the two methods in the accuracy, sensitivity, specificity, positive predictive value and negative predictive value (P > 0.05, Table 3 ).
The AUC is 0.825 and 0.830 for the ADNEX model and MRI, respectively.
Comparison of the ADNEX Model and MRI in Tumor Staging
Using the pathological results as gold standard, the ADNEX model detected 70 Compared with MRI, the ADNEX model has significantly lower accuracy and specificity, but significantly higher sensitivity for borderline tumor (P < 0.05).
For other diagnostic outcomes, the results were similar between the two methods (P > 0.05, Table 4 ). 
Discussion
Ovarian cancer is a common malignant tumor in female reproductive systems, the incidence rate ranks the third and only seconds to cervical cancer and uterine cancer. Furthermore, the incidence has been increasing recently. It has been a hot but challenging spot to find effective early diagnosis method. The advantage of the ADNEX model is that it is designed specifically for predicting and staging benign and malignant ovarian tumors in a cost effective way. It uses conventional clinical information and ultrasound data for on-line prediction, irrespective of the availability of CA125 data. For ultrasound examination, data corrected by inexperienced physician are sufficient for modeling. MRI provides images at various directions and layers, and is especially suitable for soft tissue. It can display the relationship between the various organs in the pelvic cavity and guide surgical operation although the reports may be somewhat subjective.
The Clinical Significance of the ADNEX Model in the Diagnosis of Benign and Malignant Ovarian Tumors
It was reported that when the two sets of data were used for the diagnosis of benign and malignant ovarian tumors, the accuracy of the ADNEX model was 79.9%, and 81.3%, respectively [9] . We found that the accuracy, sensitivity and specialty of the ADNEX model were 78.70%, 93%, and 72%, respectively with the positive predictive value of 60.6% and negative predictive value of 95.7%.
The accuracy is similar to the previous report. The accuracy, sensitivity, special- 
The Clinical Significance of the ADNEX Model in Staging Ovarian Tumors
Traditionally, ovarian tumor staging is mainly depended on pathological examination, not on ultrasound data. The staging results based on the ADNEX model are similar to those reported previously [9] . The accuracy and sensitivity of the ADNEX model on early stage tumors were less than on late stage tumors. For early stage tumors, the ADNEX model and MRI are similar. For borderline tumor staging, the ADNEX model is less accurate and specific but more sensitive as compared with MRI (P < 0.05). For staging tumors at other stages, the outcomes from the two methods are slightly, and statistically insignificantly different (P > 0.05). Therefore, the ADNEX model is better at ovarian tumor staging, while MRI cannot directly stage the tumors, particularly for borderline tumor.
Although the ADNEX model is not perfect but it is a big step forward in tumor staging, despite its low sensitivity to early stage tumor. For better clinical use of the ADNEX model and higher qualitative assessment and staging of benign and malignant ovarian tumors, we have identified a number of shortcomings in the ADNEX model. For example, the age input has to be ≥14; the maximum diameter of tumor must be ≥8 mm. It is desirable to improve the model making it possible to accommodate the data outside the current range for better applicability. In addition, parameters used in the model may be expended to include indexes describing lymph node enlargement, nodes in pelvic cavity and posterior fornix, blood flow signal and resistance if any. Finally, due to the retrospective nature of the study, the ultrasound data parameters collected did not strictly follow what are required in the model, and some of the data were estimated. The limited sample size may also affect the diagnostic efficacy of the ADNEX model and MRI examination. It is likely that the model would have better diagnosis performance for differentiating benign and malignant ovarian tumors and their staging if the model is modified, clinical data are collected according to the model requirement, and further prospective study is conducted.
In conclusion, our study shows the ADNEX model is clinically value for differentiating benign and malignant ovarian tumors and their staging. It is useful for detection and exclusion of ovarian tumors, although its staging ability for early stage tumor needs further improvement and validation.
